The influence of tifluadom on cholecystokinin-induced antinociception.
The effects of tifluadom, a benzodiazepine-kappa-opioid-receptor agonist, on cholecystokinin-octapeptide (CCK-8)-induced antinociception were investigated in the mouse writhing test. When given alone, tifluadom produced pronounced, dose-dependent analgesia. The antinociceptive effect of intracerebroventricularly injected CCK-8 was potentiated by high doses of tifluadom. In contrast, when tifluadom was applied at low doses which did not induce antinociception, the antinociceptive effect of CCK-8 was completely antagonized. It is concluded that tifluadom acts both as kappa-opioid receptor agonist and as an antagonist at CCK receptors mediating CCK-induced antinociception.
Gericke
M
M
Institute of Pharmacology and Toxicology of Charité, Humboldt University, Berlin, G.D.R.
Morgenstern
R
R
Ott
T
T
D000700:Analgesics; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000494:pharmacology
D000700:Analgesics; D001569:Benzodiazepines; D009020:Morphine; D002766:Cholecystokinin; C035470:tifluadom